Ortho Regenerative Technologies
16667 Hymus Boulevard
Kirkland
Québec
H9H 4R9
Canada
Tel: 512-550-8005
Website: http://www.orthorti.com/
Email: info@orthorti.com
About Ortho Regenerative Technologies
Ortho Regenerative Technologies Inc. is an orthopedic biotechnology company developing novel therapeutic tissue repair devices to dramatically improve the success rate of Sports Medicine SurgeriesWe are committed to improving patients’ lives through increasing the success rates of surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention.
YEAR FOUNDED:
2015
LEADERSHIP:
President and CEO: Ed Margerrison PhD
Executive Chairman of the Board: Steven Saviuk
CFO: Jo-Anne Piché
VP, Business Development: Jeff Skinner
JOBS:
Please click here for Ortho Regenerative Technologies's job opportunities.
PIPELINE:
Please click here for Ortho Regenerative Technologies's pipeline.
34 articles about Ortho Regenerative Technologies
-
Ortho Regenerative Technologies Announces Corporate Name Change to ChitogenX
9/7/2022
Ortho Regenerative Technologies Inc. announced that it has changed its corporate name to ChitogenX Inc. to better reflect the Company's expanded clinical and commercial opportunities, mission, values, and core competencies.
-
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL
7/27/2022
Ortho Regenerative Technologies Inc. today announced the initiation of patients' enrollment following completion of the first patient surgery in its U.S. Phase I/II rotator cuff tear repair clinical trial.
-
Ortho Regenerative Technologies Initiates Patients Recruitment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial
6/13/2022
Ortho Regenerative Technologies Inc., a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, is pleased to report on the progress of its U.S. Phase I/II rotator cuff tear repair clinical trial.
-
ORTHO REGENERATIVE TECHNOLOGIES RECEIVES $500,000 AXELYS GRANT TO ADVANCE ORTHO-M DEVELOPMENT FOR MENISCUS REPAIR
5/26/2022
Ortho Regenerative Technologies Inc. announced today that it has received, through its partnership with Polytechnique Montreal, a $500,000 non-dilutive grant from Axelys, to advance the development of its second technology platform indication, ORTHO-M, for meniscus repair.
-
ORTHO REGENERATIVE TECHNOLOGIES RECEIVES KEY U.S. COMPOSITION AND METHOD PATENT FOR ORTHO-R SOFT TISSUE REPAIR PLATFORM
5/4/2022
Ortho Regenerative Technologies Inc. announced today that the United States Patent and Trademark Office (the "USPTO") has issued a patent related to the Company's ORTHO-R soft tissue repair platform.
-
Ortho Regenerative Technologies To Participate In The 2022 Virtual Growth Conference Presented By Maxim Group LLC And Hosted By M-Vest
3/24/2022
Ortho Regenerative Technologies Inc. announced that Ortho's new CEO, Philippe Deschamps, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.
-
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES EXECUTIVE LEADERSHIP CHANGES
3/15/2022
Ortho Regenerative Technologies Inc. today announced the appointment of Philippe Deschamps as its new Chief Executive Officer following the retirement of Mr. LeDuc, the Company's CEO for the last three years.
-
Ortho Regenerative Technologies Announces $3 Million Non-Brokered Private Placement Of Units
2/11/2022
Ortho Regenerative Technologies Inc., a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced a non-brokered private placement of units for maximum gross proceeds of $3.0 million.
-
ORTHO REGENERATIVE TECHNOLOGIES ENTERS INTO A MATERIAL TRANSFER AGREEMENT WITH A GLOBAL STRATEGIC MEDICAL COMPANY FOR ITS ORTHO-R ROTATOR CUFF TEAR REPAIR PHASE I/II U.S. CLINICAL TRIAL
2/7/2022
Ortho Regenerative Technologies Inc. today announced it has entered into a Material Transfer Agreement with an undisclosed, industry-leading, global strategic medical company.
-
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES U.S. IND CLINICAL HOLD LIFTED BY THE FDA & CLEARANCE TO PROCEED WITH U.S. CLINICAL TRIAL.
12/13/2021
Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) ("Ortho" or the "Company"), announced today that the clinical hold on its U.S. Investigational New Drug ("IND") application has been lifted by the U.S. Food and Drug Administration ("FDA") and that the Company is cleared to proceed with its Phase I/II U.S clinical trial to evaluate the safety and efficacy of ORTHO-R as an adjunct treatment to standard of care surgery in rotator cuff tear repair.
-
Ortho Regenerative Technologies Submits Formal Response to U.S. FDA Clinical Hold
7/20/2021
Ortho Regenerative today announced that it has provided and filed all requested CMC-related data and characterization information in a formal response to the U.S. Food and Drug Administration.
-
Ortho Regenerative Technologies Appoints Two New Members to its Board of Directors
6/15/2021
MONTREAL, June 15, 2021 /PRNewswire/ - Ortho Regenerative Technologies Inc., a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced the appointment of Messrs.
-
Ortho Regenerative Technologies Receives Clinical Hold Letter From the U.S. FDA
6/4/2021
Ortho Regenerative Technologies Inc., a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced that it has received a clinical hold letter from the U.S.
-
Ortho Regenerative Technologies Announces Submission of Investigational New Drug Application for ORTHO-R
4/6/2021
Phase I/II clinical trial initiation for rotator cuff tear repair in the U.S. anticipated in Q2 2021
-
Ortho Regenerative Technologies Secures DTC Eligibility for the Trading of Its Shares On the US OTCQB Market
3/31/2021
Ortho Regenerative Technologies Inc . , a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that its common shares are now eligible for electronic clearing and settlement
-
Ortho Regenerative Technologies Well-positioned for Next Phase of Development
3/2/2021
MONTREAL, March 2, 2021 /PRNewswire/ - Ortho Regenerative Technologies Inc., a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, provided a review of 2020 calendar year activities and a look forward at planned future milestones as the Company transitions from preclinical to clinical stage.
-
Ortho Regenerative Technologies Adds Patrick O'Donnell to Board of Directors
2/24/2021
Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTCQB: ORTIF) a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today the appointment of Patrick O'Donnell to its Board of Directors
-
Ortho Regenerative Technologies launches AGORACOM platform for online investors outreach
2/10/2021
Ortho Regenerative Technologies Inc . ( CSE: ORTH) (OTCQB: ORTIF ) a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today the launch of a 12-month online investors outreach campaign through AGORA
-
Ortho Regenerative Technologies Retains Westwicke ICR as Investor Relations Advisors for the U.S.
2/4/2021
Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTCQB: ORTIF) (" Ortho RTI a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that it has retained Westwicke, an ICR company, as its investor relations advisors
-
Ortho Regenerative Technologies Enters Into Global License With Hanuman Pelican, Inc.
1/5/2021
Provides Ortho RTI with worldwide rights to commercialize Buoy Suspension Fractional System in combination with Ortho-R